Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy
Background: Diabetic peripheral neuropathy (DPN) is known to predict foot ulceration, lower-extremity amputation and mortality. Patients with diabetes mellitus have a predisposition toward developing chronic inflammatory demyelinating polyneuropathy, and this may also facilitate the formation of dia...
Main Authors: | Giulia Casadei, Marta Filippini, Lorenzo Brognara |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Diseases |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-9721/9/1/16 |
Similar Items
-
HbA1C Variability Is Strongly Associated With the Severity of Peripheral Neuropathy in Patients With Type 2 Diabetes
by: Yun-Ru Lai, et al.
Published: (2019-02-01) -
HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients
by: Jian-bin Su, et al.
Published: (2018-03-01) -
The Association between Cognitive Impairment and Diabetic Foot Care: Role of Neuropathy and Glycated Hemoglobin
by: Lorenzo Brognara, et al.
Published: (2020-11-01) -
The Correlation Between HbA1c and Neuropathy Disability Score in Type 2 Diabetes
by: Ilsa Hunaifi, et al.
Published: (2021-07-01) -
Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres
by: Jamie Burgess, et al.
Published: (2021-01-01)